Using the 2024 national academies of science, engineering, and medicine definition of long Covid implications for pulmonary and critical care medicine
Author(s)
Type
Journal Article
Abstract
SARS-CoV-2 emerged in late 2019, leading to the COVID-19 pandemic (1). In the initial months of the pandemic, the number of hospitalizations for respiratory failure caused by acute respiratory distress syndrome increased exponentially, and the global case fatality rate reached 3.4% with large regional variations (2, 3). An unprecedented number of research studies were launched around the globe, aiming to understand and prevent severe acute illness (4–7). Over the past 5 years, the public health impact of acute COVID-19 has evolved considerably, with increases in population-level immunity due to natural infections and the increasing availability of proven effective vaccines, antiviral agents, immunomodulators, monoclonal antibodies, and the ever-changing landscape of SARS-CoV-2 variants with reduced pathogenicity but enhanced immune evasion and infectivity (8–12).
Date Issued
2025-08-01
Date Acceptance
2025-05-19
Citation
American Journal of Respiratory and Critical Care Medicine, 2025, 211 (8), pp.1391-1396
ISSN
1073-449X
Publisher
American Thoracic Society
Start Page
1391
End Page
1396
Journal / Book Title
American Journal of Respiratory and Critical Care Medicine
Volume
211
Issue
8
Copyright Statement
© 2025 by the American Thoracic Society. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0.
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/40439483
PII: 10.1164/rccm.202410-2036PP
Subjects
Critical Care Medicine
General & Internal Medicine
Life Sciences & Biomedicine
Respiratory System
Science & Technology
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2025-08-01